Research programme: HIV infections therapy - TA TherapeuticsAlternative Names: GRN 665; GRN 951; GRN139951; GRN140665; TAT 0001; TAT 0002; TAT1; TAT2
Latest Information Update: 12 Mar 2010
At a glance
- Originator Geron Corporation; TA Therapeutics
- Class Small molecules
- Mechanism of Action Telomerase activators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical HIV infections